TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00754858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT00837564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBASP psychotherapy
Description: specific psychotherapy for chronic depression
Study: NCT03505411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin supplementation
Study: NCT04212481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniport video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two ports video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using two ports

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three ports video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using three ports
Study: NCT02117544

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses (new)

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses (new)

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Study: NCT02059161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus™
Description: Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial Insulin
Description: Participants will continue their prandial insulin during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prandial Insulin
Description: Participants will continue their prandial insulin during the study.
Study: NCT03293485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem+Cilastatin/Relebactam
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
Study: NCT01171365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Inhaled ciclesonide 320mcg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo inhaler two inhalations twice daily
Study: NCT00372528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (LYRICA)
Description: 150 mg up to a maximum of 600 mg per day bid or tid as required
Study: NCT00949962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen therapy
Description: Given systemically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given subcutaneously

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy
Study: NCT02726178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil® Pediatric drops for infants
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Study: NCT04300218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (CAU)
Description: Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual (CAU)
Description: Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
Study: NCT01511146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m2 in 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin + Gemcitabine
Description: Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
Study: NCT03977389

Intervention type: PROCEDURE
Intervention: Total wrist denervation
Description: Study of the files
Study: NCT02137551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABM
Description: The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABM
Description: The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
Study: NCT03725046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized information transmission
Description: Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
Study: NCT02556879

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Donor specific antibodies
Description: Additional samples for Donor specific antibodies at each visit

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum bank
Description: Additional samples for serum bank at each visit if possible

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA bank
Description: Additional sample for DNA bank at inclusion visit if possible

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver biopsy
Description: Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver ultrasounds and Fibroscan
Description: Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
Study: NCT01301612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week
Study: NCT01950884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe tablets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: lifestyle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: lifestyle
Study: NCT03634072

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVR
Description: Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
Study: NCT04115397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00778323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb remote ischemic preconditioning (LRIPC)
Description: LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
Study: NCT00856427

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation
Description: Undergo implantation of radio-opaque markers

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implanted fiducial-based imaging
Description: Undergo implantation of radio-opaque markers
Study: NCT03714412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of the Cardiovalve transfemoral mitral valve replacement system
Study: NCT03575468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced E-cigarette Coaching
Description: The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quitline treatment as usual
Description: The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
Study: NCT01123304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb028
Description: 1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
Study: NCT04583865

Intervention type: OTHER
Intervention: teleconsultation
Description: In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
Study: NCT00547937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure (CPAP) therapy
Description: Nocturnal ventilation through a nasal mask to avoid sleep apneas

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: nasal continuous positive airway pressure (CPAP) therapy
Description: Nocturnal ventilation through a nasal mask to avoid sleep apneas
Study: NCT01177150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-28431754/ Placebo
Description: Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-28431754
Description: Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
Study: NCT02963077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRC (A3384)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRC (A3384)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRC (A3384)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Questran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Questran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00837564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
Study: NCT03694535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bladder wall thermotherapy with Mitomycin-c
Description: application of intravesical mitomycin-C with hyperthermia
Study: NCT03911635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: URAGPI technique
Description: the Urethral Advancement, Glanuloplasty and Preputioplasty
Study: NCT00838838

Intervention type: DRUG
Intervention: Testosterone Undeconate (Nebido-R, BAY86-5037)
Description: Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
Study: NCT03791307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Pilates group
Description: The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Pilates group
Description: The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
Study: NCT01923740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V EECSS
Description: Subjects receiving XIENCE V

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS System
Description: Subjects receiving Absorb BVS System
Study: NCT01572857

Intervention type: BIOLOGICAL
Intervention: urinary excretion of FLC immunoglobulin
Description: First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.

Intervention type: BIOLOGICAL
Intervention: urinary excretion of FLC immunoglobulin
Description: First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.
Study: NCT01370863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD557
Description: 0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
Study: NCT02963077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01330446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 by mouth every morning for a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Series of questionnaires completed at different time points before, during, and at study completion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Series of questionnaires completed at different time points before, during, and at study completion.
Study: NCT03531268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PGx Testing
Description: Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
Study: NCT02059317

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
Study: NCT03946566

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.